London is hosting another key conference exploring the opportunities and advances in the biotechnology sector. The event has been organised by Oxford Global – and Future Genetics have been asked to chair the main-stage panel discussion on genomics.
Key speakers from leading companies have been invited to speak at this event.
The CEO and Medical Director of Future Genetics has been invited to chair an specialist panel discussion titled “Accelerating the Genomics Revolution“.
Dr Kamran will moderate this highly anticipated session, where the panel will comprise of Ms Sowmiya Moorthie who is a Senior Policy Analyst at the PHG Foundation, Tommi Lehtonen (CEO, Blueprint Genetics) and Mr Ali Mortazavi (CEO, Silence Therapeutics).
The two-day conference consists of an educational programme that includes over 60 presentations, postulating topics on scientific, technological and investment growth in the industry.The 2018 Biotech Investment showcase is the UK and Europe’s most focused and leading-edge funding, investment and partnering forum in the biotech sector, hosting over 200 attendees.
Please view the full agenda by clicking the below link:
Leading Venture Capitalists, funds, investors, hedge funds, emerging successful biotech spinoffs, early stage biotech discovery and clinical companies and KOLs in the sector will be attending this one of a kind showcase event on the 22nd & 23rd May 2018 in London.
It is anticipated that the event will help to identify the key technological and scientific investment areas.
Collaborate and Thrive – how to improve NHS patient outcomes by delivering better medical technologies
The NHS continues to take great strides in making a significant contribution to improving the wellness of a population that (at the same time) continues to increase in size and complexity. This introduces challenges to both public and private sector organisations and systems to meet the patient needs and demands.
The challenges on the healthcare system can be addressed in a number of ways. This includes strategies that further improve on preventing disease, with a focus on bridging differences in health inequalities. Another key approach is the need to understand gaps and differences in the care, and quality of different patient populations.
A key strategy that could add to the armamentarium of healthcare professionals would be to utilise new technology that could facilitate improving health outcomes in the UK population in the form of earlier diagnosis, better health as we age, and improved recovery from illnesses and medical interventions.
Clinical technologies need to be developed and appropriately tested for their effectiveness in delivering on their given promise in a timely manner. The process of research and development (R&D) can be a long one. As a matter of fact the vast majority of R&D companies striving to develop new medical technologies are indeed Small to Medium sized companies.
Transitioning from concept, research programmes, and testing can be daunting and a challenge. This has been realised by the UK Government and there has been significant investment to support Research companies to deliver on new and exciting medical technology that can lead to better healthcare for all.
Pictured: The Right Honourable Jacqui Smith (Chair University Hospitals Birmingham NHS Foundation Trust) and Dr Mohammed Kamran (CEO, Future Genetics)
There is a need to have an infrastructure in place to accelerate and bring to market technologies. The function of this newly purpose-built MD-TEC site is to help expedite the transition of clinically innovative technologies from the research bench through to medical utility. This would facilitate streamlining delivery for the benefit of NHS patients and the wider UK population.
Many research organisations do not have the full gamut of resources to deliver on goals. Therefore, multi-disciplinary collaboration by Research companies with NHS sites and other research and specialist organisations such as MD-TEC is critical.
The MD-TEC site provides state-of-the art facilities for Research companies. During a tour of the facility I was able to see the “pre-patient” set-up that allowed for testing of novel medical technologies and devices. This included a functioning operating theatre, A&E, and ICU facility to test technologies and devices on highly sophisticated “dummies”. Thus any unnecessary human trials or studies can be avoided. In addition, this would also facilitate the design of even better downstream clinical studies.
A functioning surgical theatre with a responsive dummy to test the robustness of medical technologies before the start of any human studies (NHS patient outcomes).
Hospital bed with monitoring technologies to help validate novel medical devices and technologies (NHS patient outcomes)
Each attendance has highlighted a common message, which is also aligned to my deep-rooted focus to contribute to the delivery of personalised medicine and care for individuals, which is the cornerstone of Future Genetics.
The common message is illustrated using my latest experience at the Diabetes Professional Care (DPC) conference and the key learnings that I have gleaned from Day 1.
Diabetes Learning No.1. Treating the Disease or the Patient? A question of perspective… and I daresay outcomes
There was a great presentation by Dr Kevin Fernando on blood glucose management, which was energetic and enthusiastically forward looking – congratulations Kevin on a fab delivery. I am of the view that he saved the best and most fundamentally important message till last (see below).
Diabetes Learning No.2. T2D Patients identified by “Opportunistic testing”. Consider this: Had they not been tested then their disease could have progressed unchecked to a more advanced stage.
With five lecture theatres and so many great sessions running simultaneously, difficult choices had to be made. I sat in on a session looking at Type 2 diabetes (T2D) in general practice, where Prof Sir Denis Pereira-Gray pointed out that 95% and 85% of T2D patients were diagnosed and managed in primary care respectively. This was followed by a presentation by Dr Kate Sidaway, PhD. She reported on findings that use of the HbA1c diagnostic test showed that the majority of “opportunistically tested” patients who were positive for T2D were asymptomatic. This demonstrated that there was an opportunity for early management of these patients, which for me opens up a key issue on what should be the basis of testing asymptomatic people?
Diabetes Learning No.3. There is an unacceptably high proportion of patients who slip through the net, so do not receive the care and management they need
The talk on Clinical Inertia by Dr Suzy Hope was great as it highlighted the challenges faced in delivering the best possible healthcare to diabetic patients. A key statistic from the Quality Outcomes Framework (QOF) data shows that 49% of diabetic patients did not undergo the full spectrum of BASIC tests (please refer to the below slide for this and other figures).
Only 20% achieve recommended levels of blood glucose, blood pressure and cholesterol
24,000 premature deaths per year due to ineffective management
80% of diabetes costs due to avoidable complications
Less than half (49%) of patients do not receive all the basic tests (QOF)
Absence of the simple tests increase risk of developing complications.
Diabetes Learning No.4. Similar to learning No.3, there is an unacceptably high proportion of patients who slip through the net, so do not receive the required personalised support to overcome BurnOut
I then went to listen to a presentation by Debbie Hicks on Diabetes Burnout which can be described as the development of a complete disregard for the management of blood sugar levels by diabetics. The speaker quoted a figure of 44% of diabetics being affected by this phenomenon, which has clear implications for the safety and wellbeing of these individuals.
Keith Vaz, MP had given a Key-note presentation around the theme of prevention being better than cure. He eloquently shared an insightful and humorous anecdote, which unfortunately I cannot fully capture here in a few words. However, the key point from my perspective was that around 10 years ago the Member of Parliament had attended an opening ceremony of a diabetes centre and gave a blood sample for the cameras (yep, the things politicians do for cameras). He was later informed that the blood had been analysed and he was an asymptomatic type-2 diabetic, which ties into the earlier talk by Dr Kate Sidaway. So, this story again emphasises the problem of not identifying patients who should ideally be managed at the earliest possible stage.
Keith Vaz informed the audience that the government invests £10 billion per annum for diabetes management, although diabetes.co.uk estimates the figure at £14 billion per year. Either way, it’s a lot of money. Whilst I like to think that the money spend is focused and hopefully wisely spent, it is clear that there are cracks that need mending with respect to helping those patients that are currently being missed by the system. Therefore, a meaningful re-think at some level is needed if we are to avoid falling foul to Einstein’s view of insanity (repeatedly doing the same thing and somehow expecting a different outcome).
Let us know your thoughts on this article, and please feel free to share any experiences you have had.